Clinical
balance. The procoagulant drive involves several zymogens and procofactors that, once activated by limited proteolysis, are able to generate thrombin, which in turn converts fibrinogen into fibrin (Fig. 1) . The anticoagulant drive consists of powerful inhibitory systems such as antithrombin (AT), activated Protein C (APC), Protein 5, and the tissue factor pathway inhibitor (Fig. 1) .' Heightened activation of coagulation zymogens may, by overwhelming the anticoagulant systems, cause a state of hypercoagulability.
This can be defined biochemically as an imbalance in the coagulation cascade through pathological activation of the corresponding enzymes in the absence of clinical signs of thrombosis [1] . The laboratory detection of this condition, occurring before clinical thrombosis is apparent, is extremely important because of its potential to identify those subjects who would benefit most from prophylaxis. Over the last few years many articles have been written on hypercoagulability, and many tests have been made available for its detection.
However, no precise guidelines have been given concerning the usefulness of these tests in the clinical laboratory.
Markers to Detect Hypercoagulability
Apart from markers of platelet and fibrinolysis activation, which will not be dealt with here, severa) approaches for laboratory detection of hypercoagulability are possible. One approach is to measure the concentrations of zymogens of the coagulation cascade, on the assumption that, when activated, their concentrations in plasma decrease. However, this approach is of little help because the concentrations of zymogens in plasma are high relative to the small amounts that are activated and consumed during the hypercoagulable state. This makes it difficult to quantify accurately very small decreases in zymogen concentrations.
Lately, other possibilities have been explored, including measurement of the fragments generated when zymogens are activated, measurement of the active enzymes, or measurement of the complexes that result from enzyme inactivation by naturally occurring plasma inhibitors.
These activation markers are stable entities with finite lifetimes and circulate in normal plasma at low concentrations.
If care is taken to avoid activation during or after blood collection, they can be used as indices of time-based clotting assay [4, 5] . Among the fragments generated from the activation of clotting factors, factor IX and factor X activation peptides (FIXP and FXP) are now assayable by immunoassays. These fragments represent indices of upstream activation of the coagulation cascade [8, 9] . Prothrombin fragment 1 + 2 (Fl +2), which results from the FXa-mediated activation of prothrombin [10] [11] [12] [13] [14] , and fibrinopeptide A (FPA), which is cleaved from the alpha chain of fibrinogen by thrombin [15] [16] [17] , are indices of thrombin generation and activity, respectively (Fig. 2) . The times for their concentrations in plasma to halve are 90 and 3 mm, respectively.
Protein C (PC), a naturally occurring coagulationinhibitor, must be activatedby thrombin bound to the endothelial receptor thrombomodulin to exert its anticoagulant action against FVIIIa and FVa. During activation, a small peptide is released from the amino-terminal end of the heavy chain of PC (Fig. 3 ). Some immunoassays are available for quantifying the PC activation peptide (PCP) or APC [18, 19] .
For PC as for coagulation activation, normal subjects have low levels of activation that are responsible for the continuous production of APC and PCP. Therefore, these measurements can be regarded as indices of thrombin-thrombomodulin function. Finally, among the enzyme-inhibitor complexes, immunoassays have been developed for thrombin-antithrombin (TAT) [11, 20] and other complexes that result from the inhibition of APC by PC inhibitor and antitrypsin [21, 22] . [30] . About 25% of patients with deficiency of AT, PC, or Protein S had higher concentrations of either Fl +2 or FPA, or both, than did normal controls. This and a subsequent study [31] confirmed and extended earlier findings that a procoagulant imbalance exists in these patients [28, 32] . However, the concentrations of activation markers found in patients with a previous thrombotic history were not significantly different from those found in patients without thrombotic history. These data suggest that measurement of activation markers is of limited value in detecting those patients with inherited thrombophilia who are most susceptible to develop thrombosis.
To establish the absolute value of the activation markers in this situation would require a prospective study of a large number of patients.
Other patients at increased risk of thrombosis are those with autoimmune disorders [33] . In a cross-sectional study, we measured markers of coagulation activation in patients with systemic lupus erythematosus with and without lupus anticoagulant and in patients with lupus anticoagulant only [34] . About 25% of patients presented with Fl +2 and FPA concentrations higher than the upper limit for normal controls. However, there were no differences between those who had a previous history of thrombosis and those who had been asymptomatic. [45, 50] . On the one hand, these differences could be explained by the different times of blood samplings, i.e., whether the patients are on the stable phase of the therapy, still in the acute phase, or long past the thrombotic event. Alternatively, they might be related to the Park Heart Study, which is currently assessing the predictive value of Fl +2 for ischemic heart disease in middleaged, apparently normal subjects [55] . Currently, the usefulness of markers of coagulation activation in diagnosing acute thrombotic events is questionable, being apparently less effective than other markers of fibrinolysis activation such as the D-dimer. Finally, the use of markers of coagulation activation to monitor anticoagulant treatment is still a premature indication and needs to be investigated by means of well-designed clinical studies.
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